DE69106549D1 - Thrombin-Zusammensetzung zur oralen Verabreichung. - Google Patents

Thrombin-Zusammensetzung zur oralen Verabreichung.

Info

Publication number
DE69106549D1
DE69106549D1 DE69106549T DE69106549T DE69106549D1 DE 69106549 D1 DE69106549 D1 DE 69106549D1 DE 69106549 T DE69106549 T DE 69106549T DE 69106549 T DE69106549 T DE 69106549T DE 69106549 D1 DE69106549 D1 DE 69106549D1
Authority
DE
Germany
Prior art keywords
oral administration
thrombin composition
thrombin
excellent solubility
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69106549T
Other languages
English (en)
Other versions
DE69106549T2 (de
Inventor
Yasuyuki Kunihiro
Ryo Tanaka
Seishichi Hata
Koji Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69106549D1 publication Critical patent/DE69106549D1/de
Publication of DE69106549T2 publication Critical patent/DE69106549T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4833Thrombin (3.4.21.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69106549T 1990-03-01 1991-03-01 Thrombin-Zusammensetzung zur oralen Verabreichung. Expired - Fee Related DE69106549T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2050494A JPH0813750B2 (ja) 1990-03-01 1990-03-01 経口用トロンビン製剤

Publications (2)

Publication Number Publication Date
DE69106549D1 true DE69106549D1 (de) 1995-02-23
DE69106549T2 DE69106549T2 (de) 1995-06-22

Family

ID=12860487

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69106549T Expired - Fee Related DE69106549T2 (de) 1990-03-01 1991-03-01 Thrombin-Zusammensetzung zur oralen Verabreichung.

Country Status (9)

Country Link
US (1) US5149540A (de)
EP (1) EP0444692B1 (de)
JP (1) JPH0813750B2 (de)
AT (1) ATE116858T1 (de)
AU (1) AU643753B2 (de)
CA (1) CA2037325A1 (de)
DE (1) DE69106549T2 (de)
DK (1) DK0444692T3 (de)
ES (1) ES2069761T3 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
US5595735A (en) * 1990-05-23 1997-01-21 Johnson & Johnson Medical, Inc. Hemostatic thrombin paste composition
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
DE4137996A1 (de) * 1991-11-19 1993-05-27 Behringwerke Ag Verfahren zur herstellung eines virussicheren thrombinkonzentrates
US6017953A (en) * 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
US5506127A (en) * 1994-09-21 1996-04-09 Proba; Zbigniew Therapeutic grade thrombin produced by chromatography
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
AU702955B2 (en) * 1996-05-17 1999-03-11 Quadrant Healthcare (Uk) Limited Microparticles and their use in wound therapy
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6264988B1 (en) 1997-06-05 2001-07-24 Hemosphere, Inc. Fibrinogen-coated microspheres
WO2001023536A1 (fr) * 1999-09-27 2001-04-05 International Reagents Corporation Stabilisation de la thrombine et compositions
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
ES2215731T3 (es) * 1999-10-12 2004-10-16 Daiichi Suntory Pharma Co., Ltd. Composiciones medicamentosas para uso oral.
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
BR0317237A (pt) 2002-12-11 2005-11-01 Ferrosan As Dispositivo para amostragem ou coleta, kit, usos de um dispositivo e de um kit, e, métodos para diminuir a quantidade de um marcador em uma área de amostra, para amostrar de modo qualitativo ou quantitativo uma área quanto ao teor de um marcador e para cultivar microorganismos ou células de mamìferos coletados
US8834864B2 (en) * 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
JP4740532B2 (ja) * 2003-09-30 2011-08-03 雪印乳業株式会社 骨形成促進及び骨吸収抑制剤
WO2005030244A1 (ja) * 2003-09-30 2005-04-07 Snow Brand Milk Products Co., Ltd. 骨形成促進及び/又は骨吸収抑制剤
EP1713521B1 (de) 2004-01-30 2010-07-28 Ferrosan A/S Hämostatische sprays und zusammensetzungen
ATE405643T1 (de) * 2004-06-22 2008-09-15 Zymogenetics Inc Thrombinzusammensetzungen
AU2005262070B2 (en) 2004-07-09 2011-01-27 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
ES2226587B1 (es) 2004-10-22 2005-12-16 Probitas Pharma, S.A. Composicion de trombina estable.
AU2007267338B2 (en) * 2006-05-31 2013-04-04 Baxter Healthcare S.A. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US20090186395A1 (en) * 2006-06-26 2009-07-23 Israel Nur Virus Removal by Nanofiltration
TWI436793B (zh) 2006-08-02 2014-05-11 Baxter Int 快速作用之乾密封膠及其使用和製造方法
US8790698B2 (en) 2007-10-30 2014-07-29 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
JP5569398B2 (ja) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー/エス 止血および/または創傷治癒を促進するための装置
US9149557B2 (en) * 2008-04-16 2015-10-06 The Chemo-Sero-Therapeutic Research Institute Process for preparing bioabsorbable sheet preparation holding thrombin
US9039783B2 (en) * 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
AU2010262058B2 (en) 2009-06-16 2013-08-29 Baxter Healthcare S.A. Hemostatic sponge
JP2013514093A (ja) 2009-12-16 2013-04-25 バクスター・インターナショナル・インコーポレイテッド 止血スポンジ
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
ES2682302T3 (es) 2010-06-01 2018-09-19 Baxter International Inc Proceso para la producción de composiciones hemostáticas secas y estables
MX344402B (es) 2010-06-01 2016-12-14 Baxter Int Inc * Proceso para elaborar composiciones hemostaticas secas y estables.
WO2011151386A1 (en) 2010-06-01 2011-12-08 Baxter International Inc. Process for making dry and stable hemostatic compositions
MX356185B (es) 2011-10-11 2018-05-17 Baxter Int Composiciones hemostaticas.
EP2766058B1 (de) 2011-10-11 2022-11-23 Baxter International Inc. Hämostatische zusammensetzungen
CN103889447B (zh) 2011-10-27 2015-11-25 巴克斯特国际公司 止血组合物
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
CA2874290C (en) 2012-06-12 2020-02-25 Ferrosan Medical Devices A/S Dry haemostatic composition
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
EP3079731B1 (de) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2433299A (en) * 1944-01-22 1947-12-23 Parke Davis & Co Blood coagulant and method of preserving same
CH264752A (de) * 1947-06-03 1949-10-31 Hoffmann La Roche Verfahren zur Herstellung von Trägern für Arzneimittel.
DE1517787A1 (de) * 1965-12-06 1970-01-29 Takeda Chemical Industries Ltd Enzympraeparat und Verfahren zu seiner Herstellung
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4363319A (en) * 1980-06-30 1982-12-14 Applied Medical Devices, Inc. Ready-to-use bandage incorporating a coagulant composition and method of preparing same
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
ATE20824T1 (de) * 1981-06-25 1986-08-15 Serapharm Gmbh & Co Kg Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung.
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
NO852655L (no) * 1985-06-05 1986-12-08 Bio Data Corp Fremgangsmaate ved fremstilling av koaguleringsreagens for blodplasma i mikrokonsentrert tablettform.
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS63243032A (ja) 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
JPH0193536A (ja) 1987-10-01 1989-04-12 Green Cross Corp:The 経口用トロンビン製剤
JP2847160B2 (ja) 1987-11-04 1999-01-13 吉富製薬株式会社 トロンビン含有医薬組成物
US4923813A (en) * 1988-01-15 1990-05-08 American Health Foundation Monoclonal antibody-based immunoassay for cyclic DNA adducts resulting from exposure to crotonaldehyde or acrolein
JPH02218618A (ja) * 1989-02-21 1990-08-31 Green Cross Corp:The トロンビン粉末製剤

Also Published As

Publication number Publication date
AU643753B2 (en) 1993-11-25
DE69106549T2 (de) 1995-06-22
JPH0813750B2 (ja) 1996-02-14
AU7199291A (en) 1991-09-05
DK0444692T3 (da) 1995-03-20
ATE116858T1 (de) 1995-01-15
CA2037325A1 (en) 1991-09-02
JPH03255035A (ja) 1991-11-13
US5149540A (en) 1992-09-22
EP0444692A1 (de) 1991-09-04
EP0444692B1 (de) 1995-01-11
ES2069761T3 (es) 1995-05-16

Similar Documents

Publication Publication Date Title
DE69106549T2 (de) Thrombin-Zusammensetzung zur oralen Verabreichung.
DK20290A (da) Formuleringer med forsinket afgivelse
DK203787A (da) Praeparat til nasal administrering
NO951630D0 (no) Fremgangsmåte for administrering av azithromycin
DE68923819T2 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE76748T1 (de) Arzneimittel fuer den bereich der mundhoehle.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
DK0760677T3 (da) Farmaceutisk præparat omfattende glucagon
NO863061L (no) Fremgangsmaate for fremstilling av fysiologisk aktive fenoksyeddiksyrederivater.
DE69212879D1 (de) Magensaftstabile pharmazeutische Formulierungen zur Oral Verbreichung von Gallensäuren
DK31088D0 (da) Blodkoaguleringsnedsaettende peptidderivater
NO169900C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (ih-azol-1-ylmetyl)substituerte benzotriazolderivater
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
NO893270D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridineddiksyrederivater.
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
SE8804628D0 (sv) New compounds
NO893142D0 (no) Fremgangsmaate for preservering av oftalmologiske opploesninger og sammensetninger for formaalet.
NO870049D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
PH27446A (en) Compound with gastric acid inhibitory effect
DE3685275D1 (de) Herstellung von 5-fluor-2'-deoxyuridin estern zur intravenoesen verabreichung.
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
DE68906132T2 (de) Flecainidacetat enthaltende Arzneizubereitung mit verzögerter Wirkstofffreigabe.
IT1136652B (it) Compesizione farmaceutica di fosfomicina in compresse da succhiare

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee